Call for Abstract
Scientific Program
6th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit, will be organized around the theme “Advance Approaches in Discussion of Current Issues & Future Possibilities in Bioavailability and Bioequivalence Studies”
BABE-2015 is comprised of 13 tracks and 70 sessions designed to offer comprehensive sessions that address current issues in BABE-2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Liquisolid technology for bioavailability
- Track 1-2Applications of prodrugs in BA/BE studies
- Track 1-3Bioequivalence studies of oral drugs on fasting and fed conditions
- Track 1-4Versatility of new therapeutic systems and their uses in systemic delivery
- Track 1-5Earlier exposure on BA/BE
- Track 1-6Food effect on bioavailability studies
- Track 3-1 Consideration of parallel designs for drugs with long half-lives
- Track 3-2Carbon nano tubes (CNTS) in drug designs
- Track 3-3Adaptive designs: An alternative approach to sequential designs
- Track 3-4Phase zero trials (micro dosing), boon or bane in drug development
- Track 3-5Mechanism in drug development
- Track 3-6Structure based strategies of drug design
- Track 4-1Statistical issues in drug developmenrt
- Track 4-2Regulatory initiatives to promote the use of pharmacogenomics in drug development
- Track 4-3Investigation of new drugs
- Track 4-4Relevance of bioequivalence in approving generic copies of drug products
- Track 4-5Electronic regulatory submission and review
- Track 4-6Drug application regulatory compliance
- Track 4-7New drug quality assessment
- Track 5-1Cost, quality and productivity metrics
- Track 5-2Geographical considerations in bioequivalence testing
- Track 5-3Documented standard operating procedures
- Track 5-4Identification and monitoring protocol specified serious adverse events
- Track 6-1Genetic engineering approaches employed to improve bioavailability
- Track 6-2Effect of genetic polymorphisms on pharmacokinetics
- Track 6-3Use of genomic techniques
- Track 7-1Invitro and Invivo techniques for investigating drug metabolisim
- Track 7-2Assessment of pharmaceutical quality and in-vivo performance of generic drugs
- Track 7-3Impact of physical and chemical properties of drug
- Track 7-4Issues and concerns pertaining to bioavailability and bioequivalence
- Track 8-1Solubility based on highest dose strength of an IR product
- Track 8-2Requirements for acquiring BCS based waiver for in-vivo BA/BE studies
- Track 8-3Establishment of bioequivalence criteria
- Track 8-4Drugs possessing narrow therapeutic index
- Track 8-5Volume of distribution
- Track 8-6Waivers of In Vivo Study Requirements
- Track 8-7Biopharmaceutics Classification System (BCS)
- Track 9-1Analysis of BA/BE by oral vs parentral
- Track 9-2Criterion for bioequivalence confidence interval approach
- Track 9-3 Parametric vs non-parametric tests
- Track 9-4 Bioequivalence of endogenous substances
- Track 9-5 Plasma concentration vs time curve (AUC) based dosing
- Track 9-6Adverse drug reactions
- Track 10-1Bioavailability of nutrients and fed bioequivalence studies
- Track 10-2Factors playing a critical role in absorption of nutraceuticals
- Track 10-3Enhancers of nutrient bioavailability
- Track 10-4The role of BPDM nutrient bioavailability
- Track 11-1Recent developments on behavioral pharmacology
- Track 11-2Clinical toxicology
- Track 11-3Pharmacogenetics
- Track 11-4Clinical and experimental pharmacology
- Track 11-5Clinical drug developments & therapeutics
- Track 11-6Recent developments on posology
- Track 12-1Randomized, two-period, two-sequence, single dose cross-over design, parallel design and replicate designs
- Track 12-2Absolute bioavailability
- Track 12-3Relative bioavailability
- Track 12-4Pharmacokinetics & pharmacodynamics
- Track 13-1Absorption
- Track 13-2Food Effect
- Track 13-3Drug metabolism/ biotransformation
- Track 13-4Energy dependent efflux transporters
- Track 13-5Physico-chemical factors
- Track 13-6First pass metabolism
- Track 13-7CYP450 isozymes